Lactucopicrin Inhibits Cytoplasmic Dynein-Mediated NF-κB Activation in Inflammated Macrophages and Alleviates Atherogenesis in Apolipoprotein E-Deficient Mice

Mol Nutr Food Res. 2021 Feb;65(4):e2000989. doi: 10.1002/mnfr.202000989. Epub 2021 Jan 22.

Abstract

Scope: Nuclear factor-κB (NF-κB) activation in macrophages aggravates atherosclerosis. Dietary plant secondary metabolites including sesquiterpene lactone lactucopicrin target multiple organs. This study is focused on the impact of lactucopicrin on NF-κB activation in inflammed macrophages and atherogenesis in a mouse model of atherosclerosis.

Methods and results: In LPS-stimulated mouse bone marrow-derived macrophages, lactucopicrin inhibits NF-κB activation, and concomitantly represses the expression of IL-1β, IL-6, and tumor necrosis factor-alpha. This effect is not due to modulation of the inhibitor of NF-κB kinases (IKK) α/β/γ and NF-κB inhibitor α, and NF-κB/p65 DNA binding activity. Instead, the lactucopicrin effect is reliant on the inhibition of cytoplasmic dynein-mediated p65 transportation, a prerequisite step for p65 nuclear translocation. In high-fat diet-fed apolipoprotein E-deficient mice, lactucopicrin consumption dose-dependently reduces plaque area, inhibits plaque macrophage accumulation, attenuates plaque macrophage NF-κB activation, and reduces both plaque and serum inflammatory burden. However, lactucopicrin consumption does not affect the levels of serum lipids and anti-inflammatory cytokines (IL-4, IL-10, and transforming growth factor beta).

Conclusion: Dietary lactucopicrin inhibits atherogenesis in mice likely by its anti-inflammatory property. These findings suggest that dietary supplementation with lactucopicrin is a promising strategy to inhibit atherosclerotic cardiovascular disease.

Keywords: atherosclerosis; dynein; lactucopicrin; macrophage; nuclear factor-κB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis / drug therapy*
  • Cytoplasm / metabolism
  • Dyneins / metabolism
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Inflammation / pathology
  • Lactones / pharmacology*
  • Macrophages / drug effects*
  • Macrophages / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout, ApoE
  • NF-kappa B / metabolism*
  • Plaque, Atherosclerotic / drug therapy
  • Plaque, Atherosclerotic / metabolism
  • Plaque, Atherosclerotic / pathology
  • Protein Transport / drug effects
  • Sesquiterpenes / pharmacology*
  • Transcription Factor RelA / metabolism

Substances

  • Lactones
  • NF-kappa B
  • Rela protein, mouse
  • Sesquiterpenes
  • Transcription Factor RelA
  • intybin
  • Dyneins